Oncternal Therapeutics (ONCT)
(Delayed Data from NSDQ)
$1.50 USD
+0.04 (2.74%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $1.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ONCT 1.50 +0.04(2.74%)
Will ONCT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ONCT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ONCT
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates
Stevanato Group (STVN) Q2 Earnings Match Estimates
ONCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy
Other News for ONCT
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Oncternal Therapeutics announces updated data from Phase 1/2 study of ONCT-534
Oncternal Therapeutics announces updated data from Phase 1/2 study of ONCT-534
12 Health Care Stocks Moving In Tuesday's Pre-Market Session